MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

NCT06611163 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2026-03-25

No results posted yet for this study

Summary

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Conditions

  • Moderate to Severe Genital Psoriasis

Interventions

DRUG

Tildrakizumab 100 mg

Tildrakizumab 100 mg SC injection on Day 1, Week 4 and every 12 weeks thereafter

DRUG

Placebo

Placebo SC injection at Day 1 and Week 4

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-21
Primary Completion
2026-01-21
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Georgia
  • Hungary
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06611163 on ClinicalTrials.gov